Roche: Stefan Frings. Developing personalised cancer care through rational integration of diagnostics and therapeutics




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Roche: Stefan Frings. Developing personalised cancer care through rational integration of diagnostics and therapeutics
Released on: May 23, 2013. © PharmaTelevision Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    In this episode of PharmaTelevision News Review, filmed at Bio Conference 2013, in Chicago, USA, Fintan Walton talks to Stefan Frings.
  • Summary
  • Transcript
  • Participants
  • Company
In this episode of PharmaTelevision News Review, filmed at Bio Conference 2013, in Chicago, USA, Fintan Walton talks to Stefan Frings.
In this episode of PharmaTelevision News Review, filmed at Bio Conference 2013, in Chicago, USA, Fintan Walton talks to Stefan Frings.
Stefan Frings
Avalon Ventures
Roche
As a research-focused healthcare company, Roche discovers, develops and provides innovative diagnostic and therapeutic products and services that deliver significant benefits to patients and healthcare professionals – from early detection and prevention of diseases to diagnosis, treatment, and treatment monitoring. Roche was founded on October 1st, 1896. The founder, Fritz Hoffmann-La Roche, was among the first to recognize that the industrial manufacture of standardized medicines would be a major advance in the fight against disease. From the very beginning, Roche’s visionary founder focused his company on innovation and on establishing an international presence. This multinational presence reinforces our ability to offer our healthcare solutions and to anticipate needs in all regions of the world. Today, Roche employs over 80,000 people and sells its products in over 150 countries. Today Roche ranks among the world’s leading healthcare companies and has two strong core businesses: diagnostics and pharmaceuticals. Roche’s prime objective is to identify and meet the patient’s and customers’ needs. This implies solving their problems and anticipating their future needs by maintaining close contact with them and listening to what they say. At Roche we focus our resources on two research intensive businesses: pharmaceuticals and diagnostics. Within these businesses we prioritise those areas of significant unmet need where we have the expertise to make a difference. Our aim is to develop new and improved drugs, diagnostic tests and services offering significant benefits over existing options. By innovation we mean the creation and commercialisation of medically differentiated products and services that lead to a tangible improvement to the health, quality and length of patients’ lives. As a research-focused company we exploit the latest discoveries and technologies to develop our products. Roche invested over 8 billion Swiss francs in 2011 on research and development. Roche continues its longstanding tradition of working in alliances with some of the most forward-looking and technologically advanced companies in the world. Roche invests heavily in biotechnology and is the world’s largest biotechnology company.